Alain Gey

Alain Gey

Auto-generated profile, based on publicly available information

Alain Gey

Université Paris Cité, INSERM, PARCC, PARIS France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
NBNadine Benhamouda
Nadine Benhamouda
ISIkuan Sam
Ikuan Sam
NENicolas Epaillard
Nicolas Epaillard
AGAlain Gey
Alain Gey
LPLetuan Phan
Letuan Phan
Eric TartourEric Tartour
Eric Tartour
Purpose: CD70 is a costimulatory molecule known to activate CD27-expressing T cells. CD27–CD70 interaction leads to the release of soluble CD27 (sCD27). Clear-cell renal cell carcinoma (ccRCC) expresses the highest levels of CD70 among all solid tumors; however, the clinical consequences of CD70 expression remain unclear. Experimental Design: Tumor tissue from 25 patients with ccRCC was assessed for the expression of CD27 and CD70 in situ using multiplex immunofluorescence. CD27+ T-cell phenotypes in tumors were analyzed by flow cytometry and their gene expression profile were analyzed by single-cell RNA sequencing then confirmed with public data. Baseline sCD27 was measured in 81 patients with renal cell carcinoma (RCC) treated with immunotherapy (35 for training cohort and 46 for validation cohort). Results: In the tumor microenvironment, CD27+ T cells interacted with CD70-expressing tumor cells. Compared with CD27− T cells, CD27+ T cells exhibited an apoptotic and dysfunctional signature. In patients with RCC, the intratumoral CD27–CD70 interaction was significantly correlated with the plasma sCD27 concentration. High sCD27 levels predicted poor overall survival in patients with RCC treated with anti–programmed cell death protein 1 in both the training and validation cohorts but not in patients treated with antiangiogenic therapy. Conclusions: In conclusion, we demonstrated that sCD27, a surrogate marker of T-cell dysfunction, is a predictive biomarker of resistance to immunotherapy in RCC. Given the frequent expression of CD70 and CD27 in solid tumors, our findings may be extended to other tumors.

1 November 2014 in The Journal of OncoPathology
Verified
Journal Article
Closed access
CGClémence Granier
Clémence Granier
Helene et RousselHelene et Roussel
Helene et Roussel
EGEleonore De Guillebon
Eleonore De Guillebon
SLSylvain Ladoire
Sylvain Ladoire
AGAlain Gey
Alain Gey
Eric TartourEric Tartour
Eric Tartour

1 April 2023
Verified
Other
Open access
NBNadine Benhamouda
Nadine Benhamouda
ISIkuan Sam
Ikuan Sam
NENicolas Epaillard
Nicolas Epaillard
AGAlain Gey
Alain Gey
LPLetuan Phan
Letuan Phan
Eric TartourEric Tartour
Eric Tartour
Supplementary Table from Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma

1 April 2023
Verified
Other
Open access
NBNadine Benhamouda
Nadine Benhamouda
ISIkuan Sam
Ikuan Sam
NENicolas Epaillard
Nicolas Epaillard
AGAlain Gey
Alain Gey
LPLetuan Phan
Letuan Phan
Eric TartourEric Tartour
Eric Tartour
Supplementary Table from Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma

1 April 2023
Verified
Other
Open access
NBNadine Benhamouda
Nadine Benhamouda
ISIkuan Sam
Ikuan Sam
NENicolas Epaillard
Nicolas Epaillard
AGAlain Gey
Alain Gey
LPLetuan Phan
Letuan Phan
Eric TartourEric Tartour
Eric Tartour
Supplementary Data from Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma

31 March 2023
Verified
Other
Open access
CGClémence Granier
Clémence Granier
CDCharles Dariane
Charles Dariane
PCPierre Combe
Pierre Combe
VVVirginie Verkarre
Virginie Verkarre
SUSaik Urien
Saik Urien
Eric TartourEric Tartour
Eric Tartour
Figure S1 : Heterogeneous distribution of various subpopulations of intratumor CD8+T cells defined by the differential expression of PD1 and Tim-3 using an in situ multiparametric immunofluorescence technique. Figure S2: PD-1 and Tim-3 co-expression on CD8+T cells (in situ IF analyzis) correlates with clinical parameters of RCC aggressiveness Figure S3 : Relationships between the total number of intratumor T cells and subpopulations of CD8+T cells and Progression Free Survival Figure S4: Heterogeneous distribution of various subpopulations of tumor-infiltrating CD8+T cells defined by the differential expression of PD1 and Tim-3 analyzed by cytometry Figure S5: Patients who co-expressed PD-1 and Tim-3 on CD8+T cells more often exhibited clear cell RCC histology Figure S6: Tim-3 expression was decreased on PD-1+CD8+T cells after treatment with collagenase Figure S7 : PD-1 and Tim-3 expression on renal cell carcinoma by in situ immunofluorescence analysis Figure S8 : Blockade experiments with anti-PD-1 and anti-Tim-3 on bulk TIL